GoodRx HoldingsGDRX
GDRX
About: GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Employees: 694
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
53% more call options, than puts
Call options by funds: $6.04M | Put options by funds: $3.95M
3.36% more ownership
Funds ownership: 140.71% [Q2] → 144.08% (+3.36%) [Q3]
1% more funds holding
Funds holding: 163 [Q2] → 165 (+2) [Q3]
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
5% less capital invested
Capital invested by funds: $1.04B [Q2] → $986M (-$49.6M) [Q3]
21% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 47
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
35%
upside
Avg. target
$6.33
43%
upside
High target
$7
58%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Morgan Stanley Craig Hettenbach 60% 1-year accuracy 3 / 5 met price target | 35%upside $6 | Equal-Weight Maintained | 17 Dec 2024 |
Citigroup Daniel Grosslight 41% 1-year accuracy 7 / 17 met price target | 58%upside $7 | Buy Maintained | 13 Nov 2024 |
Barclays Stephanie Davis 56% 1-year accuracy 9 / 16 met price target | 35%upside $6 | Overweight Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 5 articles about GDRX published over the past 30 days
Neutral
Business Wire
3 days ago
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time). A live webcast will be available on the Company's Investor Relations website, https://investors.
Neutral
Business Wire
4 days ago
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today revealed startling healthcare disparities in its new report, “Endocrinologist Deserts: A Critical Healthcare Gap for Millions in the U.S.” With nearly 70% of U.S. counties lacking an endocrinologist, the report paints a stark picture of the barriers millions of Americans face in managing life-threatening conditions like diabetes. The findings come at a critical time as the.
Neutral
Business Wire
5 days ago
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role. Wendy will join GoodRx following her role as CEO of RxBenefits, where she led the company in providing pharmacy benefit su.
Positive
CNBC
2 weeks ago
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
Prescription fills for blockbuster weight loss medications in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments. That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Neutral
Business Wire
2 weeks ago
GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today released a new Weight Loss Medications Tracker that provides an inside look at fill trends and spending patterns for weight loss medications across the U.S. The company found that limited insurance coverage and high out-of-pocket costs aren't slowing down interest in popular drugs used for weight loss such as Mounjaro, Ozempic, Wegovy, and Zepbound. In fact, some of these p.
Neutral
Business Wire
1 month ago
GoodRx Helps Announces Recipients of 2024 Students for Healthcare Equity Scholarship
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Helps, a 501(c)(3) nonprofit organization seeking to address health inequities across the country, has selected its 2024 Students for Healthcare Equity Scholarship recipients. The scholarship program was created to encourage culturally responsive healthcare by providing financial assistance to healthcare students from underrepresented groups. To date, GoodRx Helps has granted $325,000 in scholarships to students advocating for equitable access to he.
Neutral
PRNewsWire
1 month ago
Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm
NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, GoodRx insiders caused the company to misrepresent or fail to disclose that (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescription transactions revenue (the Company's primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx's revenues for purchases at Kroger's pharmacies; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
Neutral
Business Wire
1 month ago
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This.
Neutral
GlobeNewsWire
1 month ago
GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company.
Neutral
The Motley Fool
1 month ago
Why GoodRx Holdings Stock Was Sinking This Week
The company is growing key fundamentals. However, the improvements weren't enough to impress the market.
Charts implemented using Lightweight Charts™